Parkinson’s Disease Market Size, Share, Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast To 2022 Parkinson’s disease (PD) is the second common neurodegenerative disease after Alzheimer’s. It usually affects people above the age of 50 with symptoms of bradykinesia and rigidity being the most common. It is caused by the loss of dopamine-producing neurons within the basal ganglia. As the disease progresses, it leads to disability in patients restricting major motor functions. PD is difficult to diagnose without a medical history or neurological examination. Patients in the advanced stages suffer from shaking and difficulty of swallowing and chewing. Other symptoms include depression, impaired balance, and urinary problems. Anticholinergics can control the tremors mixed with levodopa. Carbidopa delays the conversion of levodopa before it changes to dopamine. Other dopamine agonists include pramipexole, ropinirole, and bromocriptine mimic the same role as dopamine. The market currently offers drugs which offer symptomatic relief. The global geriatric population is the major driver of Parkinson’s disease drug market. But the need for a diseasemodifying drug will drive the market demand over the years ahead. The market is projected to reach about USD 5 billion by 2022. For further information on this report, please visit http://www.radiantinsights.com/research/frontier-pharma-parkinsons-disease Levodopa is the current reigning drug in the market among other dopamine agonists and Monoamine Oxidase B (MAO-B). Germany, Spain, Japan, Italy, United States, United Kingdom, and France are major sales regions for the market. Despite new drug therapies and dopaminenergic drugs, the market is at risk of being offset by generic competition. Launch of Xadago and Rytary are expected to improve drug sales for the market till 2022. Other drugs in the pipeline include Intec’s CD/LD-GR, Bial’s opicapone, Biotie’s tozadenant, and Acorda’s CVT-301. MAO-B inhibitors increase the dopamine levels by breaking the metabolism within the basal ganglia. They can be used to improve motor functions and restrict the use of levodopa. Alternatives to drugs is treatment with surgery. Three different types of surgery available are deep brain stimulation (DBS), transplantation or restorative, and ablative surgery. But less than 10% of patients qualify for surgery and chances of risk are higher than palliative care prescribed by doctors. Key manufacturers that produce drugs to counter the effects of Parkinson’s disease are GlaxoSmithKline, AbbVie, Lundbeck, Novartis, and Merck. Table Of Content:
1 Table of Contents 2 1.1 List of Tables 3 1.2 List of Figures 3 2 Executive Summary 4 2.1 High Unmet Needs Remain in Parkinson’s Disease Market 4 2.2 Diverse and Innovative Pipeline to Shift Focus to Disease Modification 4 2.3 Deals Landscape Presents Substantial Investment Opportunities 4 3 The Case for Innovation 5 3.1 Growing Opportunities for Biologic Products 6 3.2 Diversification of Molecular Targets 6 3.3 Innovative First-in-Class Product Developments Remain Attractive 6 3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7 3.5 Sustained Innovation 7 3.6 GBI Research Report Guidance 8 Request Free Sample Of This Study @ http://www.radiantinsights.com/research/frontierpharma-parkinsons-disease#tabs-4 4 Clinical and Commercial Landscape 9 4.1 Disease Overview 9 4.2 Epidemiology 9 4.3 Disease Etiology 10 4.3.1 Exposure to Environmental Toxins 10 4.3.2 Genetic Causes of Familial Parkinson’s Disease 10 4.3.3 Susceptibility Genes for Parkinson’s Disease 12 4.4 Disease Pathophysiology 12 4.4.1 Basal Ganglia Anatomy and Physiology 12 4.4.2 Process Underlying Neurodegeneration 15 4.5 Disease Symptoms 19 4.6 Co-morbidities and Complications 19 4.7 Diagnosis 19 4.8 Classification of Disease Stages 20 4.8.1 Hoehn and Yahr Scale 20 4.8.2 Unified Parkinson’s Disease Rating Scale 20 4.8.3 Scale for the Assessment of Positive Symptoms 22 4.8.4 Mini Mental State Examination 22 4.9 Prognosis and Disease Staging 22 4.10 Treatment Options 23
4.10.1 Pharmacotherapy 23 4.10.2 Non-pharmacological Treatment 25 4.11 Overview of Marketed Products 25 4.11.1 Molecule Type and Target Analysis 26 4.11.2 Treatment Algorithm 27 4.12 Current Unmet Needs 33 5 Assessment of Pipeline Product Innovation 35 5.1 Parkinson’s Disease Pipeline by Molecule Type, Phase and Therapeutic Target 35 5.2 Comparative Distribution of Programs between Parkinson’s Disease Market and Pipeline by Therapeutic Target Family 40 5.3 First-in-Class Pipeline Programs Targeting Novel Molecular Targets 40 6 Signaling Pathways, Genetics and Innovation Alignment 45 6.1 The Complexity of Signaling Networks in the Central Nervous System 45 6.2 Signaling Pathways and First-in-Class Molecular Target Integration 46 6.3 First-in-Class Target Matrix Assessment 46 Browse All Reports of This Category @ http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare 7 First-in-Class Target Evaluation 49 7.1 Pipeline Programs Targeting α-synuclein 49 7.2 Pipeline Programs Targeting DJ-1 52 7.3 Pipeline Programs Targeting Parkin 54 7.4 Pipeline Programs Targeting High Affinity Nerve Growth Factor Receptor 56 7.5 Pipeline Programs Targeting C-jun N-Terminal Kinase 58 7.6 Pipeline Programs Targeting Leucine-Rich Repeat Kinase 2 60 7.7 Pipeline Programs Targeting Growth Hormone Secretagogue Receptor Type 1 62 7.8 Pipeline Programs Targeting Metabotropic Glutamate Receptor 4 64 7.9 Pipeline Programs Targeting NAD-dependent Protein Deacetylase Sirtuin-2 67 7.10 Overview of Pipeline Programs Targeting Progranulin 68 7.11 Conclusion 71 8 Deals and Strategic Consolidations 72 8.1 Industry-Wide First-in-Class Deals 72 8.2 Licensing Deals 73 8.3 Co-development Deals 77 8.4 First-in-Class Programs not Involved in Licensing or Co-development Deals 80 9 Appendix 82
9.1 Abbreviations 82 9.2 Bibliography 84 9.3 Research Methodology 93 9.4 Secondary Research 94 9.4.1 Marketed Product Heatmaps and Treatment Algorithm 94 9.4.2 Pipeline Analysis 94 9.4.3 First-in-Class Matrix Assessment 94 9.4.4 First-in-Class Target Profiles 95 9.4.5 Licensing and Co-development Deals 95 9.5 Contact Us 95 9.6 Disclaimer 95 About Us Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of Ancillary services such as, research partnerships/ tie-ups and customized research solutions. Media Contact: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales@radiantinsights.com Website: Radiant Insights Visit Our Blog: radiantri.blogspot.com